Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
September 2014

Inhaled Loxapine
An inhalation powder formulation of loxapine (Adasuve) has been approved by the FDA to treat acute agitation resulting from schizophrenia or bipolar I disorder in adults.

Lithium in the Elderly
Elderly patients taking low doses of lithium to attenuate the course of Alzheimer disease experience more overall adverse effects than placebo-treated patients, most notably weight gain, diabetes mellitus, and cardiac arrhythmia.

Antipsychotic-Induced Weight Gain and Other Adverse Metabolic Effects: Purported Antidotes
When switching agents is not feasible and diet and exercise are ineffective, current evidence points to metformin (Glucophage and others) as the best antidote for antipsychotic-induced weight gain.

In Brief
Venlafaxine Recall Due to Dissolution Failure; Interventions to Reduce Smoking Are Associated with Decreases in Suicide Risk

SSRIs and QT Prolongation
A recent meta-analysis found varying degrees of QT interval prolongation among selective serotonin reuptake inhibitors (SSRIs).

About the BTP Newsletter

Our subscribers say BTP is…

"Very relevant, practical, and thought-provoking."

"About the only thing left without drug ads...objective and balanced."

"Succinct, readable, clear, timely and relevant!"

"Well written and scientifically sound."

Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.

From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.

Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.

We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.